Tremmas Ioannis, Petsatodis George, Potoupnis Michael, Laskou Stella, Giannakidis Dimitrios, Mantalovas Stylianos, Koulouris Charilaos, Katsaounis Athanasios, Pavlidis Efstathios, Amaniti Aikaterini, Huang Haidong, Bai Chong, Shi Dongchen, Dardas Athanasios, Zarogoulidis Paul, Sardeli Chrisanthi, Konstantinou Fotis, Katsikogiannis Nikolaos, Zarogoulidis Konstantinos, Karapantzos Ilias, Karapantzou Chrysanthi, Shen Xiaping, Kesisoglou Isaak, Sapalidis Konstantinos
Orthopaedic Department, "Limassol" General Hospital, Cyprus.
1st Orthopaedic Surgery Department, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Greece.
J Cancer. 2018 Apr 19;9(10):1731-1736. doi: 10.7150/jca.24785. eCollection 2018.
Due to the severity of the primary disease in patients with lung cancer, quality of life (QoL) is often overlooked. Factors that form QoL should be taken in consideration when planning the appropriate treatment and determining therapy targets, because of the increasing frequency of bone metastasis leading to high levels of pain. Purpose of this study is to assess quality of life in patients with lung cancer, before and after treatment combined with zoledronic acid. QoL was assessed in 80 patients (49 males-31 females), of which 45 developed bone metastasis. Prior and post treatment (with co administration of zoledronic acid) seven reliable scales: Pittsburgh Sleep Quality index (PSQI), Epworth Sleeping Scale (ess), Dyspnea Scale (ds), Fatigue Severity Scale (FSS), Brief Pain Inventory (BPI), Fact-G scale for sleep quality and EQ-5D for general health condition. Statistically positive correlations were verified between PSQI-DS, PSQI-FSS, BPI-ESS, DS-FSS, DS-BPI and BPI-FSS (p<0,005) prior and post treatment. Patients sleep quality was improved, pain levels decreased and betterment in quality of life was marked (p<0,001). Although significant decrease in fatigue levels was observed (p<0,001) there has been an increase in dyspnea symptoms (p<0,001). Significant improvement was apparent when zoledronic acid was co administered in any treatment in patients with lung cancer. Sleep quality, fatigue and pain parameters also improved, with no positive impact on the symptoms of dyspnea.
由于肺癌患者原发疾病的严重性，生活质量（QoL）常常被忽视。在规划适当的治疗方案和确定治疗靶点时，应考虑构成生活质量的因素，因为骨转移频率增加会导致高水平的疼痛。本研究的目的是评估肺癌患者在联合使用唑来膦酸治疗前后的生活质量。对80例患者（49例男性 - 31例女性）进行了生活质量评估，其中45例发生了骨转移。在治疗前和治疗后（联合使用唑来膦酸）使用了七个可靠的量表：匹兹堡睡眠质量指数（PSQI）、爱泼华嗜睡量表（ess）、呼吸困难量表（ds）、疲劳严重程度量表（FSS）、简明疼痛问卷（BPI）、睡眠质量的Fact - G量表和一般健康状况的EQ - 5D量表。治疗前后，PSQI - DS、PSQI - FSS、BPI - ESS、DS - FSS、DS - BPI和BPI - FSS之间经统计学验证存在正相关（p<0.005）。患者的睡眠质量得到改善，疼痛水平降低，生活质量有显著提高（p<0.001）。尽管观察到疲劳水平显著降低（p<0.001），但呼吸困难症状有所增加（p<0.001）。在肺癌患者的任何治疗中联合使用唑来膦酸时，均有明显的显著改善。睡眠质量、疲劳和疼痛参数也有所改善，但对呼吸困难症状没有积极影响。
